Guo, Jie
Qiu, Di
Gu, Han-wen
Wang, Xing-ming
Hashimoto, Kenji http://orcid.org/0000-0002-8892-0439
Zhang, Guang-fen
Yang, Jian-jun http://orcid.org/0000-0001-6785-9627
Article History
Received: 15 October 2022
Revised: 28 December 2022
Accepted: 6 January 2023
First Online: 20 January 2023
Competing interests
: Dr. Hashimoto is the inventor of filed patent applications on “The use of <i>R</i>-ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, “<i>R</i>-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder”, and “TGF-β1 in the treatment of depression” by Chiba University. Dr. K. Hashimoto has also received speakers’ honoraria, consultant fees, or research support from Abbott, Boehringer Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Sumitomo Pharma, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. The other authors declare that they have no conflicts of interest.